| Drug Name |
Gazyva |
| Drug ID |
BADD_D01007 |
| Description |
Obinutuzumab is a humanized monoclonal antibody used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia. It was approved by the FDA in November 2013 and is marketed under the brand name Gazyva. There is a black box warning of fatal Hepatitis B Virus (HBV) reactivation and fatal Progressive Multifocal Leukoencephalopathy (PML). |
| Indications and Usage |
Obinutuzumab is used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia. |
| Marketing Status |
approved; investigational |
| ATC Code |
L01FA03 |
| DrugBank ID |
DB08935
|
| KEGG ID |
D09321
|
| MeSH ID |
C543332
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D0S8WA
|
| NDC Product Code |
50242-070 |
| UNII |
Not Available
|
| Synonyms |
obinutuzumab | RO 5072759 | RO5072759 | RO-5072759 | R 7159 | R7159 cpd | R-7159 | GA 101 | GA101 antibody | GA-101 | Gazyva | gazyvaro | afutuzumab |
